

612. Acute Lymphoblastic Leukemia: Clinical Studies: Insights in Genomics, MRD, and Toxicities

[Watch Session](#)

582 [NUTM1-Rearranged Infant and Pediatric B Cell Precursor Acute Lymphoblastic Leukemia: A Good Prognostic Subtype Identified in a Collaborative International Study](#) **according to ASH clinically relevant abstract**

Judith M. Boer, Maria Grazia Valsecchi, Femke M. Hormann, et al.

583 [Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes](#)

Nicholas J. Short, Hagop M. Kantarjian, Keyur Patel, et al

584 [Multiparameter Flow Cytometry \(MFC\) of Cerebrospinal Fluid \(CSF\) from Adults Receiving Hypercvad for Acute Lymphoblastic Leukemia/Lymphoma \(ALL\) Identifies Patients at Higher Risk of Central Nervous System \(CNS\) Relapse: A Single-Center Retrospective Analysis](#)

Kelsey-Leigh A Garcia, Philip A. Stevenson, Sindhu Cherian, et al.

585 [The Association between Asparaginase Enzyme Activity Levels and Toxicities in Childhood Acute Lymphoblastic Leukaemia in the NOPHO ALL2008 Protocol](#) **according to ASH clinically**

relevant abstract

Line Stensig Lynggaard, Lisbeth Moeller, Cecilie Utke Rank, et al.

586 [Pegaspargase Re-Challenge after Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results from DFCI 16-001](#)

Lynda M. Vrooman, Yael Flamand, Victoria Koch, et al.

587 [Orthopedic Toxicity Among Adolescents and Young Adults Treated on DFCI ALL Consortium Trials](#) according to ASH clinically relevant abstract

Yannis K. Valtis, Kristen E. Stevenson, Andrew E. Place, et al.